Francis Medical Inc.
Privately held medical device company developing a convective water‑vapor thermal ablation platform and associated transurethral devices for focal treatment of urologic cancers (prostate, kidney, bladder). Core activities include device R&D, multicenter clinical studies (early feasibility to pivotal), regulatory interactions with the U.S. FDA, and capital raises to support clinical development and commercialization. Leadership includes experienced clinical investigators and former regulatory officials supporting clinical and regulatory strategy.
Industries
N/A
Nr. of Employees
small (1-50)
Francis Medical Inc.
7351 Kirkwood Lane N., Suite 130, Maple Grove, MN 55369
Products
Water‑vapor ablation system (transurethral device)
A medical device platform that converts sterile water to vapor and delivers stored thermal energy via a transurethral catheter to ablate targeted urologic tissues.
Water‑vapor ablation system (transurethral device)
A medical device platform that converts sterile water to vapor and delivers stored thermal energy via a transurethral catheter to ablate targeted urologic tissues.
Services
Sponsor‑led multicenter clinical studies including site initiation, enrollment, endpoint definition and follow‑up for device safety and efficacy.
Sponsor‑led multicenter clinical studies including site initiation, enrollment, endpoint definition and follow‑up for device safety and efficacy.
Expertise Areas
- Clinical trial management for medical devices
- Minimally invasive urologic device development
- Regulatory strategy and FDA interactions (IDE, Breakthrough Device, 510(k) planning)
- Thermal ablation therapies and convective energy delivery
Key Technologies
- Water‑vapor thermal ablation
- Convective thermal energy delivery
- Transurethral minimally invasive delivery
- Focal ablation techniques for urologic cancers
News & Updates
Company announced completion of enrollment for the VAPOR 2 pivotal clinical study evaluating the water‑vapor ablation therapy for prostate cancer.
Company announced an $80 million Series C financing to fund the VAPOR 2 study and U.S. launch activities.
Announcement of the first patient treated in the VAPOR 2 pivotal clinical study.
Company received U.S. FDA Breakthrough Device designation for its minimally invasive water‑vapor ablation therapy for prostate cancer.
Press release announcing the appointment of Dr. Jonathan Jarow as Chief Medical Officer to lead clinical and regulatory efforts, including oversight of the VAPOR trials.
Publication of six‑month primary endpoint VAPOR 1 data showing safety and efficacy outcomes for water‑vapor ablation in intermediate‑risk localized prostate cancer.
Company announced completion of enrollment for the VAPOR 2 pivotal clinical study evaluating the water‑vapor ablation therapy for prostate cancer.
Company announced an $80 million Series C financing to fund the VAPOR 2 study and U.S. launch activities.
Announcement of the first patient treated in the VAPOR 2 pivotal clinical study.
Company received U.S. FDA Breakthrough Device designation for its minimally invasive water‑vapor ablation therapy for prostate cancer.
Press release announcing the appointment of Dr. Jonathan Jarow as Chief Medical Officer to lead clinical and regulatory efforts, including oversight of the VAPOR trials.
Publication of six‑month primary endpoint VAPOR 1 data showing safety and efficacy outcomes for water‑vapor ablation in intermediate‑risk localized prostate cancer.